Sarah Verhoeff

91 [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in R/M SCCHN patients PET-imaging analyses In total, 24 patients underwent [89Zr]Zr-DFO-durvalumab PET-imaging using an antibody dose of 10 mg. In these patients, [89Zr]Zr-DFO-durvalumab tumor accumulation was measured for all [18F]FDG positive tumor lesions (n=53). The [89Zr]Zr-DFO-durvalumab uptake, lesion size and lesion location are displayed in Figure 3. [89Zr]Zr-DFO-durvalumab PET imaging. For quantitative analyses of [89Zr]Zr-DFO-durvalumab, 53 lesions were included. No significant differences were observed between lesions in different organ sites. However, accumulation of [89Zr]Zr-DFO-durvalumab was highly variable in tumor lesions within and between patients, which is illustrated in Figure 3 and 4. Figure 3. Scatterplot of all [18F]-FDG-positive lesions (n=53) measuring ≥10mm (or 15mm in lymph node) and their corresponding [89Zr]Zr-DFO-durvalumab-uptake. Lesions were distributed over lung (n=20), lymph nodes (n=18), local recurrence (n=8), bone (n=5) and liver (n=1). 5